Pfizer and BioNTech to Request Emergency Authorization for Kids 5-11 to Receive COVID Booster

1,859
BioNTech
Developed in tandem by Pfizer and BioNTech, the two companies asked for approval from the Food and Drug Administration (FDA) to issue an emergency authorization for children aged 5 to 11 to be able to receive additional COVID-19 boosters. File photo: Marco Lazzarini, Shutter Stock, licensed.

WASHINGTON, D.C. – Pfizer and BioNTech announced this week that they will be requesting an emergency authorization from the Food and Drug Administration (FDA) to administer COVID-19 vaccine booster shots to healthy children in the 5 to 11 age range.

Pfizer and BioNTech had conducted a study – which has not been published or independently vetted – where they gave a group of 140 children a third shot six months after they had originally been fully immunized with their initial two-shot dose.

The researchers claim that “a robust response was observed regardless of prior SARS-CoV-2 infection.”

Pfizer reps claim that the children experienced a 6-fold increase in antibodies against SARS-CoV-2, and a sub-analysis of 30 children in the study showed a 36-fold increase in neutralizing antibody titers.

However, recent data presented to the FDA’s vaccine advisory panel on April 6 indicates that COVID-19 vaccines currently provide as a little as 17 percent protection against infections of variants of the virus – which currently make up the vast majority of new cases – indicating that those to receive the jab are still likely to catch the disease as those who haven’t.

Despite the current batch of vaccines on the market – including Pfizer’s – offering little in the way of protection against being infected with COVID-19 variants, studies do indicate that they remain effective in preventing “severe illness” associated with the virus.

But only a small percentage of children suffer severe disease from SARS-CoV-2 infections, leading some experts to speculate that – considering some of the side-effects associated with COVID-19 vaccines – if the benefits outweigh the risks, or vice versa.

Comment via Facebook

Corrections: If you are aware of an inaccuracy or would like to report a correction, we would like to know about it. Please consider sending an email to [email protected] and cite any sources if available. Thank you. (Policy)


Comments are closed.